Sees FY24 revenue $1.603B-$1.618B, consensus $1.62B. “The company’s guidance for 2024 revenue and adjusted earnings per share reflects the stability of our markets and strong demand for our differentiated portfolio, gradual improvement in supply over the year, continued international expansion and the relaunch of the Boston portfolio late second quarter. Our guidance excludes the pending acquisition of the Acclarent ENT business.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
- Integra LifeSciences Announces Leadership Transition Plan
- Is IART a Buy, Before Earnings?
- Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
- Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
